Skip to Main content Skip to Navigation
Journal articles

Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.

Abstract : Highly active antiretroviral therapy is recommended for HIV-infected pregnant women to prevent mother-to-child transmission. The specific physiological background induced by pregnancy leads to significant changes in maternal pharmacokinetics, suggesting potential variability in plasma concentrations of antiretrovirals during gestation. Therapeutic drug monitoring (TDM) of protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) is recommended in certain situations, including pregnancy, but its systematic use in HIV-infected pregnant women remains controversial. This review provides an update of the pharmacokinetic data available for PIs and NNRTIs in pregnant women and highlights the clinical interest of systematic TDM of certain antiretroviral drugs during pregnancy, including nevirapine, nelfinavir, saquinavir, indinavir and lopinavir.
Document type :
Journal articles
Complete list of metadata
Contributor : Matthieu Roustit Connect in order to contact the contributor
Submitted on : Tuesday, February 17, 2009 - 9:33:14 AM
Last modification on : Friday, November 6, 2020 - 4:10:16 AM
Long-term archiving on: : Saturday, November 26, 2016 - 5:46:27 AM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




Matthieu Roustit, Malik Jlaiel, Pascale Leclercq, Françoise Stanke-Labesque. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.. British Journal of Clinical Pharmacology, Wiley, 2008, 66 (2), pp.179-95. ⟨10.1111/j.1365-2125.2008.03220.x⟩. ⟨inserm-00361996⟩



Record views